Fingerprint
Dive into the research topics of 'Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos, David Li, Peter A. Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen, Stephen L. Hauser
Research output: Contribution to journal › Article › peer-review
467
Scopus
citations